BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 18785547)

  • 1. [Analysis on susceptibility of ocular bacterial pathogens to four kinds of fluoroquinolone].
    Wang ZQ; Li L; Li R; Luo SY; Bai XQ; Liang QF; Deng SJ; Sun XG
    Zhonghua Yan Ke Za Zhi; 2008 Mar; 44(3):233-6. PubMed ID: 18785547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [In vitro fluoroquinolone resistance in ocular bacterial isolates].
    Sun XG; Wang ZQ; Li R; Chen L; Jin XY; Luo SY
    Zhonghua Yan Ke Za Zhi; 2003 Mar; 39(3):163-6. PubMed ID: 12880574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The changes of ocular bacterial isolates and in vitro antimicrobial susceptibility in the past six years].
    Sun ST; Wang LY; Zhang YQ; Chen ZJ; Han L; Yue J
    Zhonghua Yan Ke Za Zhi; 2012 Jun; 48(6):542-7. PubMed ID: 22943811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of in vitro susceptibilities of Gram-positive cocci isolated from ocular infections against the second and fourth generation quinolones at a tertiary eye care centre in South India.
    Reddy AK; Garg P; Alam MR; Gopinathan U; Sharma S; Krishnaiah S
    Eye (Lond); 2010 Jan; 24(1):170-4. PubMed ID: 19229279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The resistance patterns of normal ocular bacterial flora to 4 fluoroquinolone antibiotics.
    Park SH; Lim JA; Choi JS; Kim KA; Joo CK
    Cornea; 2009 Jan; 28(1):68-72. PubMed ID: 19092409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gatifloxacin and moxifloxacin: an in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates.
    Kowalski RP; Dhaliwal DK; Karenchak LM; Romanowski EG; Mah FS; Ritterband DC; Gordon YJ
    Am J Ophthalmol; 2003 Sep; 136(3):500-5. PubMed ID: 12967804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activity of fluoroquinolones against ocular bacterial isolates in São Paulo, Brazil.
    Oliveira AD; D'Azevedo PA; Francisco W
    Cornea; 2007 Feb; 26(2):194-8. PubMed ID: 17251812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro susceptibilities of bacterial ocular isolates to fluoroquinolones.
    Graves A; Henry M; O'Brien TP; Hwang DG; Van Buskirk A; Trousdale MD
    Cornea; 2001 Apr; 20(3):301-5. PubMed ID: 11322420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of newer fluoroquinolones against gram-positive and gram-negative bacteria isolated from ocular infections: an in vitro comparison.
    Duggirala A; Joseph J; Sharma S; Nutheti R; Garg P; Das T
    Indian J Ophthalmol; 2007; 55(1):15-9. PubMed ID: 17189881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [In vitro antibiotic susceptibility to fluoroquinolones].
    Wong CA; Galvis V; Tello A; Villareal D; Rey JJ
    Arch Soc Esp Oftalmol; 2012 Mar; 87(3):72-8. PubMed ID: 22423655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can antimicrobial susceptibility testing results for ciprofloxacin or levofloxacin predict susceptibility to a newer fluoroquinolone, gatifloxacin?: Report from The SENTRY Antimicrobial Surveillance Program (1997-99).
    Jones RN; Pfaller MA;
    Diagn Microbiol Infect Dis; 2001 Apr; 39(4):237-43. PubMed ID: 11404067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluoroquinolone resistance in bacterial isolates from ocular infections: Trend in antibiotic susceptibility patterns between 2005-2020.
    Chatterjee S; Agrawal D; Gomase SN; Parchand SM; Gangwe AB; Mishra M
    Indian J Ophthalmol; 2022 Dec; 70(12):4391-4398. PubMed ID: 36453351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative in-vitro efficacy of fluoroquinolones against Streptococcus pneumoniae recovered from bacterial keratitis as determined by E-test.
    Ramakrishnan R; Ramesh S; Bharathi MJ; Amuthan M; Viswanathan S
    Indian J Pathol Microbiol; 2010; 53(2):276-80. PubMed ID: 20551532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review of third-and fourth-generation fluoroquinolones in ophthalmology: in-vitro and in-vivo efficacy.
    Scoper SV
    Adv Ther; 2008 Oct; 25(10):979-94. PubMed ID: 18836691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fourth generation fluoroquinolones: new weapons in the arsenal of ophthalmic antibiotics.
    Mather R; Karenchak LM; Romanowski EG; Kowalski RP
    Am J Ophthalmol; 2002 Apr; 133(4):463-6. PubMed ID: 11931779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro susceptibility of recent gram-positive isolates to ciprofloxacin, levofloxacin, and trovafloxacin.
    Isenberg HD; Alperstein P; France K
    Diagn Microbiol Infect Dis; 1998 Oct; 32(2):115-8. PubMed ID: 9823535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging fluoroquinolone resistance in bacterial keratitis: a 5-year review.
    Goldstein MH; Kowalski RP; Gordon YJ
    Ophthalmology; 1999 Jul; 106(7):1313-8. PubMed ID: 10406613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An in vitro resistance study of levofloxacin, ciprofloxacin, and ofloxacin using keratitis isolates of Staphylococcus aureus and Pseudomonas aeruginosa.
    Kowalski RP; Pandya AN; Karenchak LM; Romanowski EG; Husted RC; Ritterband DC; Shah MK; Gordon YJ
    Ophthalmology; 2001 Oct; 108(10):1826-9. PubMed ID: 11581056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin.
    Bauernfeind A
    J Antimicrob Chemother; 1997 Nov; 40(5):639-51. PubMed ID: 9421311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationships among ciprofloxacin, gatifloxacin, levofloxacin, and norfloxacin MICs for fluoroquinolone-resistant Escherichia coli clinical isolates.
    Becnel Boyd L; Maynard MJ; Morgan-Linnell SK; Horton LB; Sucgang R; Hamill RJ; Jimenez JR; Versalovic J; Steffen D; Zechiedrich L
    Antimicrob Agents Chemother; 2009 Jan; 53(1):229-34. PubMed ID: 18838594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.